Asgard & CleanSpace's¬†Cleanroom Specification Initiative¬†uses best practice when considering¬†cGMP cleanrooms¬†or any GxP controlled environment, from project inception¬†through¬†detailed design, frequently considering how a correctly written cleanroom specification will impact¬†a¬†project design and the performance of the built asset at occupation and throughout its life cycle.
We use guidance¬†from the following¬†professional¬†associations when developing design and specifications, including the following:
Asgard and CleanSpace also consider¬†cost management and safety when developing client specifications as well as¬†constructability.
It is our endeavor¬†to assist¬†biopharmaceutical¬†clients and design¬†firms to develop project specifications using the most up to¬†date material technologies¬†as well as¬†disruptive¬†and innovative¬†technologies¬†based on over 20 years of¬†experience¬†delivering cleanroom projects across Europe.
We are also delighted to be in a position to transfer this experience and knowledge¬†base to our colleagues¬†in CleanSpace, LLC in the US.
We strongly believe our initiative will create¬†continuity throughout our global design community¬†with more consistent and¬†uniform specifications.
Ultimately, all facilities¬†should be delivered to the same high quality standards, using globally cleanroom compliant materials¬†and methods.
This¬†initiative¬†will enhance¬†our clients‚Äô¬†successful operation when manufacturing life saving medicines and therapies.